3-Bromo-6-nitro-2-piperazinylquinoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-Bromo-6-nitro-2-piperazinylquinoline
• 英文别名: 3-Bromo-6-nitro-2-piperazin-1-yl-quinoline；3-bromo-6-nitro-2-piperazin-1-ylquinoline
• 化学式: C₁₃H₁₃BrN₄O₂
• 分子量: 337.176
• InChiKey: MPHPQAKQQDLIGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  74
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-氯-6-硝基喹啉 在 sodium bromate 、 硫酸 、 氢溴酸 、 溶剂黄146 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 25.5h， 生成 3-Bromo-6-nitro-2-piperazinylquinoline
  参考文献：
  名称：

  Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1

  摘要：

  6-Nitroquipazine has been known as one of the most potent and selective inhibitors of serotonin transporter in vitro and in vivo. Nine derivatives of 6-nitroquipazine were synthesized and tested for their potential abilities to displace [H-3]citalopram binding to the rat cortical membranes. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00290-0

文献信息

• Substituted 6-nitroquipazines, methods of preparation, and methods of use
  申请人：The Regents, University of California

  公开号：US05372813A1

  公开（公告）日：1994-12-13

  Disclosed is a substituted 6-nitroquipazine of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are each selected from the group consisting of H, Fl, CL, Br, I, CF.sub.3, CH.sub.2 CH.sub.2 F, CH.sub.3, CH.sub.2 CH.sub.3, and --CH(CH.sub.3).sub.2, and wherein one of R.sub.1, R.sub.2, R.sub.3, and R.sub.4 is other than H. Also disclosed is a method for measurement of serotonin uptake sites in a sample, in which a radioligand is incubated with a sample and then the radioactivity of the radioligand bound to the sample is determined, utilizing a radio labeled substituted 6-nitroquipazine as the radioligand. Also disclosed is a method of manufacture and method of use.

  本发明公开了一种式为##STR1## 的取代6-硝基喹嗪，其中R.sub.1、R.sub.2、R.sub.3和R.sub.4分别选自H、Fl、Cl、Br、I、CF.sub.3、CH.sub.2 CH.sub.2 F、CH.sub.3、CH.sub.2 CH.sub.3和--CH(CH.sub.3).sub.2的群组，其中R.sub.1、R.sub.2、R.sub.3和R.sub.4中的一个不是H。本发明还公开了一种测量样品中5-羟色胺摄取位点的方法，其中将放射性配体与样品孵育，然后测定配体与样品结合的放射性，并利用放射性标记的取代6-硝基喹嗪作为放射性配体。本发明还公开了一种制造方法和使用方法。
• Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same
  申请人：Chi Dae-Yoon

  公开号：US20050165006A1

  公开（公告）日：2005-07-28

  Novel quinoline derivatives were prepared and evaluated their pharmaceutical activities. The quinoline derivatives according to the present invention effectively bind serotonin transporter (SERT) which is called serotonin reuptake site. Serotonin is one of the neurotransmitter and the lack of its concentration in synapse cause the depression. The quinoline derivatives in this invention can interrupt reuptake of serotonin into presynaptic neuron resulting the increasement of concentration of serotonin in synapse as well as stimulating the signal through the binding with serotonin recepter. Thus, they can be used for the prevention and treatment of mental disorder, especially depression, caused by the deficiency of serotonin concentration in synapse.

  通过本发明制备了新型喹啉衍生物，并评估了它们的药物活性。本发明的喹啉衍生物能够有效地结合血清素转运体（SERT），也称为血清素再摄取位点。血清素是一种神经递质，如果突触中缺乏其浓度，则会导致抑郁症。本发明中的喹啉衍生物可以中断血清素重新摄取到突触前神经元中，从而增加突触中血清素的浓度，并通过与血清素受体结合刺激信号。因此，它们可以用于预防和治疗由突触中血清素浓度不足引起的心理障碍，特别是抑郁症。
• US5372813A
  申请人：——

  公开号：US5372813A

  公开（公告）日：1994-12-13
• [EN] QUINOLINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME<br/>[FR] DERIVES DE QUINOLINE, PREPARATIONS DE CES DERIVES ET COMPOSITIONS PHARMACEUTIQUES COMPRENANT CES DERIVES
  申请人：CHEMON INC

  公开号：WO2003082286A1

  公开（公告）日：2003-10-09

  Novel quinoline derivatives were prepared and evaluated their pharmaceutical activities. The quinoline derivatives according to the present invention effectively bind serotonin transporter (SERT) which is called serotonin reuptake site. Serotonin is one of the neurotransmitter and the lack of its concentration in synapse cause the depression. The quinoline derivatives in this invention can interrupt reuptake of serotonin into presynaptic neuron resulting the increasement of concentration of serotonin in synapse as well as stimulating the signal through the binding with serotonin recepter. Thus, they can be used for the prevention and treatment of mental disorder, especially depression, caused by the deficiency of serotonin concentration in synapse.
• Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1
  作者：Byoung Se Lee、Soyoung Chu、Byung Chul Lee、Dae Yoon Chi、Yearn Seong Choe、Kyung Ja Jeong、Changbae Jin

  DOI：10.1016/s0960-894x(00)00290-0

  日期：2000.7

  6-Nitroquipazine has been known as one of the most potent and selective inhibitors of serotonin transporter in vitro and in vivo. Nine derivatives of 6-nitroquipazine were synthesized and tested for their potential abilities to displace [H-3]citalopram binding to the rat cortical membranes. (C) 2000 Elsevier Science Ltd. All rights reserved.